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Abstract
Smoking is regarded as a major risk factor for the development of cardiovascular diseases (CVD). This study investigates whether serelaxin
(RLX, recombinant human relaxin-2) endowed with promising therapeutic properties in CVD, can be credited of a protective effect against cigar-
ette smoke (CS)-induced vascular damage and dysfunction. Guinea pigs exposed daily to CS for 8 weeks were treated with vehicle or RLX,
delivered by osmotic pumps at daily doses of 1 or 10 lg. Controls were non-smoking animals. Other studies were performed on primary guinea
pig aortic endothelial (GPAE) cells, challenged with CS extracts (CSE) in the absence and presence of 100 ng/ml (17 nmol/l) RLX. In aortic
specimens from CS-exposed guinea pigs, both the contractile and the relaxant responses to phenylephrine and acetylcholine, respectively, were
significantly reduced in amplitude and delayed, in keeping with the observed adverse remodelling of the aortic wall, endothelial injury and
endothelial nitric oxide synthase (eNOS) down-regulation. RLX at both doses maintained the aortic contractile and relaxant responses to a con-
trol-like pattern and counteracted aortic wall remodelling and endothelial derangement. The experiments with GPAE cells showed that CSE sig-
nificantly decreased cell viability and eNOS expression and promoted apoptosis by sparkling oxygen free radical-related cytotoxicity, while RLX
counterbalanced the adverse effects of CSE. These findings demonstrate that RLX is capable of counteracting CS-mediated vascular damage
and dysfunction by reducing oxidative stress, thus adding a tile to the growing mosaic of the beneficial effects of RLX in CVD.
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Introduction
Smoking is regarded as one of the major risk factors for the develop-
ment of cardiovascular diseases (CVD), accounting for 80% increased
risk for coronary artery insufficiency in smokers compared with non-
smokers [1]. Recently, the World Health Organization (WHO) pre-
dicted that, by 2030, deaths related to cigarette smoke (CS) will
increase up to eight million individuals per year worldwide [2]. This
trend is expected to increase in parallel with the earlier onset of
tobacco use. Furthermore, clinical studies have shown that young
smokers have a higher risk to develop vascular functional and histo-
logical abnormalities which are early hallmarks of atherosclerosis
[3, 4]. Hence, there is a major interest in the development of new
therapeutic strategies that can prevent or reduce the adverse effects
of CS on the cardiovascular system. Increasing evidence supports the
knowledge that oxidative stress and inflammation provide the patho-
physiological link between cigarette smoking and CVD [5–10].
Endothelial dysfunction is one of the earliest pathological events that
occur in the development of CVD [7]. Several clinical and experimen-
tal studies indicate that CS oxidants can directly impair endothelial
function, primarily through a lack of nitric oxide bioavailability which
results both from decreased nitric oxide formation by the dysfunc-
tional endothelium and increased nitric oxide scavenging by oxygen
free radicals [10–13]. There is conflicting evidence regarding regula-
tion of endothelial nitric oxide synthase (eNOS) by CS extract (CSE) at
the transcriptional/translational level in cellular models with some
suggesting reduced eNOS mRNA/protein levels [14–16] while others
demonstrating unchanged [17] or even increased eNOS levels [18]:
the latter possibly likely represents an attempt of endothelial cells to
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compensate for eNOS impairment. These functional alterations are
accompanied by histological changes in vascular wall consisting in
increase in the intima-media wall thickness, a marker of early
atherosclerosis, [4, 18, 19], elastic fibres damage, cytoplasmic vac-
uolation of smooth muscle cells of the intima-media, and endothelial
loss caused by disruption of the adhesion between endothelial cells
and their basement membrane [20, 21].
On the above grounds, we designed the present study to investi-
gate whether serelaxin (RLX), the recombinant molecule correspond-
ing to the human hormone relaxin-2 [22], shown to possess
promising therapeutic properties in cardiac diseases [23, 24], may be
credited of a protective effect against CS-induced vascular damage
and dysfunction. This working hypothesis is based on the following
mainstays: (i) blood vessels are a physiological target of RLX and
their cells express the specific RLX receptor RXFP1 [25]; (ii) RLX up-
regulates NOS expression and nitric oxide production in vascular
endothelial cells [26–30]; (iii) RLX improves inflammation-induced
endothelial dysfunction and NOS fall [31, 32]; and (iv) RLX reduces
oxidative stress and nitric oxide failure in different animal models of
vascular injury [33–37].
Materials and methods
Reagents
Serelaxin was kindly provided by the RRCA Relaxin Foundation
(Florence, Italy); its use in the present animal model is supported by
the recent finding that human relaxin can bind to RXFP1 relaxin recep-
tor of various species, including the guinea pig [38]. Acetylcholine was
from Sigma Chemical (St. Louis, MO, USA), phenylephrine from Tocris
Bioscience (Bristol, UK). Kentucky Reference cigarettes 3R4F, each con-
taining 11 mg of total particulate matter, 9.4 mg of tar and 0.73 mg of
nicotine, were obtained from the Kentucky Tobacco Research Council
(Lexington, KY, USA). Unless otherwise specified, the other reagents
used for the experiments were from Sigma-Aldrich (Milan, Italy).
In vivo study
Exposure of guinea pigs to CS
Male Hartley albino guinea pigs weighing 300–350 g were used for the
experiments (Harlan, Correzzana, Italy). Animal handling and use com-
plied with the European Community guidelines for animal care (2010/63/
EU) and were approved by the Committee for Animal Care and Experi-
mental Use of the University of Florence. The animals were housed on a
12 hrs light/dark cycle at 22°C room temperature and had free access to
food and water. The experiments were designed to minimize pain and
the number of animals used. Sacrifice was carried out by decapitation.
The animals were divided into the following experimental groups
(n = 6/group):
Group 1: Control untreated animals;
Group 2: Animals exposed daily to CS for 8 weeks;
Group 3: Animals exposed daily to CS for 8 weeks and treated
with RLX given by continuous subcutaneous (s.c.) infusion using
osmotic minipumps (Alzet; DURECT Corporation, Cupertino, CA,
USA). The pumps were implanted 1 day before starting the expo-
sure to CS on the back upon anaesthesia (i.p. injection of ketamine
hydrochloride, 100 mg/kg b.w. and xylazine, 15 mg/kg b.w.) and
filled to deliver a daily dose of 1 lg for the whole duration of CS
exposure;
Group 4: Animals exposed to CS and treated with RLX given by
minipumps as above, but delivering a daily RLX dose of 10 lg for
the whole duration of CS exposure.
The animals were subjected to CS exposure in a smoke chamber,
according to Das et al. [39] with minor modifications. The smoke
chamber (2.5 l) was similar to a vacuum desiccator equipped with an
open tube for cigarette positioning at one end and a vacuum-connected
tube and stopcock at the opposite end. To each group of CS-exposed
animals, five 3R4F reference cigarettes were administered daily. Each
cigarette was fitted on the inlet tube and lit; then, a puff of CS was
introduced into the chamber containing the animals by applying a mild
suction of 4 cm water for 20 sec. The guinea pigs were exposed to the
accumulated smoke for further 40 sec., for a total duration of CS expo-
sure of 60 sec. After a pause of 60 sec. during which the chamber was
opened and ventilated with fresh air, a second puff was administered
with the same procedure. The gap between each of the 5 cigarettes/day
was 1 hr. At the end of the treatment, the animals were anaesthetized
by i.p. injection of ketamine hydrochloride (100 mg/kg b.w.) and xyla-
zine (15 mg/kg b.w.), blood and tissue samples were collected and pro-
cessed for functional, morphological and biochemical analyses.
Determination of serum RLX levels
The circulating RLX levels were determined in guinea pig serum by
ELISA (R&D Systems, Minneapolis, MN, USA) according to the manu-
facturer’s instructions.
Functional studies
Segments of thoracic aortas were cut into helical strips (3 mm width,
20 mm length) and connected to a force displacement transducer (Grass
FT03, Grass Technologies, Middleton, WI, USA) coupled to a polygraph
(Grass 7K, Grass Technologies) for continuous recording of isometric ten-
sion. Strips were mounted in 5-ml organ baths containing Krebs–Hense-
leit solution, gassed with 95% O2–5% CO2 mixture, of the following
composition (mM): NaCl 118, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, NaHCO3
25, CaCl2 2.5 and glucose 10 (pH 7.4) and kept at 37°C. Preparations
were allowed to equilibrate for 1 hr under an initial load of 2.5 g, as previ-
ously reported [40]. In each experimental group, the contractile responses
to phenylephrine (2 9 107 M) were evoked. When contraction reached
a stable plateau phase, acetylcholine (Ach, 2 9 106 M) was added. The
chosen concentrations are similar to those previously used for similar
purposes [40, 41]. The interval between two subsequent applications of
phenylephrine was ≥15 min., during which repeated washes with Krebs–
Henseleit solution were performed.
Morphological studies
Aortic tissue samples taken at sacrifice were fixed by immersion in 3%
paraformaldehyde, dehydrated in graded ethanol, embedded in paraffin
and cut in 5-lm thick sections. Histological slides were stained with
haematoxylin and eosin. Other tissue samples were fixed in 4%
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glutaraldehyde and 1% osmium tetroxide and embedded in Epon 812.
Ultrathin sections were stained with uranyl acetate and alkaline bismuth
subnitrate and examined under a JEM 1010 electron microscope (Jeol,
Tokyo, Japan) at 80 kV.
Immunohistochemical detection of eNOS
Endothelial nitric oxide synthase immunoreactivity was determined on
paraformaldehyde-fixed, paraffin-embedded sections incubated with rab-
bit polyclonal anti-eNOS (1:100, 4°C overnight; Abcam, Milan, Italy) and
Alexa-fluor 568-labelled goat anti-rabbit IgG (1:300, 1 hr at room tem-
perature; Invitrogen, Milan, Italy). Negative controls were carried out by
omitting the primary antiserum.
Determination of 8-hydroxy-20-deoxyguanosine
8-hydroxy-20-deoxyguanosine (8-OHdG), an indicator of oxidative DNA
damage, was measured in guinea pig serum with high sensitivity 8-
OHdG Check ELISA kit (IMKOGHS, Jaica, Japan), according to the man-
ufacturer’s instructions. Serum samples were passed through an ultrafil-
ter with a 10 kD molecular weight cut-off (YM-10; Millipore Co.,
Bedford, MA, USA) to remove any large molecular weight substances
and then used for 8-OHdG determination.
Detection of free carbon monoxide in plasma
Free carbon monoxide (CO) was measured in the plasma of the animals
of the different experimental groups as an index of the degree of expo-
sure to CS. The amount of free CO in plasma was measured with a gas-
eous CO detector (RGA3, Reduction Gas Analyzer; SAES Getters, Milan,
Italy) as described [42]. Measurements were obtained by comparison
with a CO standard curve prepared immediately before analysis and
expressed as parts per million.
In vitro study
Cigarette smoke extracts preparation
Cigarette smoke extracts solution was prepared by bubbling smoke
from two 3R4F cigarettes, 30 sec. each, in 50 ml of PBS according to
Niu et al. [43], with minor modifications. The resulting solution,
assumed as 100% CSE, was adjusted to pH 7.4, and filtered through a
0.2 lm filter (Millipore Co.). Cigarette smoke extracts solution was
freshly prepared on the day of the experiment and immediately used.
To establish the effective dose of CSE, preliminary concentration-
and time-dependent studies were performed (data not shown). Guinea
pig aortic endothelial cells were exposed to 1–15% CSE for 4–12 hrs
and cell viability was evaluated by trypan blue. Accordingly, 10% CSE
solution (vol/vol) for 4 hrs was used in all the experiments because it
gave a well-appreciable toxic effect without causing massive cell
death.
Isolation and culture of guinea pig aortic endothelial cells
Male Hartley albino guinea pigs (Harlan), 2- to 3-month old, were
anaesthetized by i.p. injection of ketamine hydrochloride (100 mg/kg
b.w.) and xylazine (15 mg/kg b.w.) and killed by decapitation. The tho-
racic aorta was quickly removed and guinea pig aortic endothelial
(GPAE) cells were isolated based on a previously described method
[44].
Characterization of the isolated GPAE cells was performed by
immunocytochemistry and cytochemistry, as previously reported [27].
The percentage of immunoreactive cells for endothelial markers, such
as vimentin and von Willebrand factor ranged between 96% and 98%
(data not shown). For all experiments, cells were used at the first and
second passage.
Guinea pig aortic endothelial cells were pre-treated or not with RLX
100 ng/ml (17 nmol/l) for 24 hrs and then exposed to CSE for 4 hrs.
This RLX dose was chosen because it was shown to induce significant
cell protection from oxidative stress [45]. Control cultures not exposed
to CSE were also prepared.
Total RNA extraction and RT-PCR
Expression levels of mRNA for RXFP1, eNOS and b-actin were assayed
by RT-PCR in GPAE cells. One microgram of total RNA, extracted with
TRIzol Reagent (Invitrogen), was reverse transcribed and amplified with
SuperScript One-Step RT-PCR System (Invitrogen). After cDNA synthe-
sis for 30 min. at 55°C, the samples were pre-denatured for 2 min at
94°C and then subjected to 35 cycles of PCR performed at 94°C for
15 sec., alternating with 55°C for 30 sec. (RXFP-1 and b-actin) or 57°C
for 30 sec. (eNOS) and 72°C for 1 min.; the final extension step was
performed at 72°C for 5 min. The following guinea pig gene-specific
primers were used: RXFP1 (XM_003476825.2), forward 50-GGT TGC
TTG GTT GGT TCT GT-30 and reverse 50-ACG TTG GGA GGG AGT TTT
CT-30; eNOS (NM_001172985), forward 50-CCT GCT TCA TTA GAG GGG
CT-30 and reverse 50-TCG ACA GCC AAA CAC CAA AG-30; b-actin
(NM_001172909.1), forward 50-CTT TGC TGC GTT ACA CCC TT-30 and
reverse 50-ATG CTT GCT CCA ACC AAC TG-30. PCR products were elec-
trophoresed on a 2% agarose gel and stained with ethidium bromide.
Trypan blue viability assay
The trypan blue exclusion method was used to assess cell viability. Gui-
nea pig aortic endothelial cells (5 9 104/well) were seeded in 24-well
plates. At the end of the treatments, the cells were gently detached by
trypsin/ethylenediaminetetraacetic acid (EDTA), resuspended in culture
medium and mixed 1:1 with 0.4% trypan blue solution. The final cell
suspensions were counted under a phase contrast inverted microscope
using a Burker chamber. Viable cells were expressed as percentage of
the total counted cells.
Mitochondrial membrane potential
Mitochondrial membrane potential (Dw) was assessed as previously
reported [46] using tetramethylrhodamine methyl ester perchlorate
(TMRM), a lipophilic potentiometric fluorescent dye that distributes
between mitochondria and cytosol in proportion to Dw by virtue of its
positive charge. Thus, the fluorescence intensity depends on dye accu-
mulation in mitochondria, which is directly related to Dw. For confocal
microscope analysis, GPAE cells were cultured on glass coverslips and
loaded for 20 min. at 37°C with TMRM, dissolved in 0.1% dimethylsulf-
oxide (DMSO) to a 100 nM final concentration in the culture medium.
The cells were fixed in 2% paraformaldehyde for 10 min. at room tem-
perature and the TMRM fluorescence analysed under a confocal Leica
TCS SP5 laser scanning microscope (Mannheim, Germany) with 543-
nm excitation wavelength and 963 oil immersion objective. Dw was
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also quantified by flow cytometry: single-cell suspensions were incu-
bated for 20 min. at 37°C in the dark with TMRM dissolved in M199
medium (100 nM) and then analysed using a FACSCanto flow cytometer
(Becton-Dickinson, San Jose, CA, USA).
Assessment of Caspase-3 activity
Guinea pig aortic endothelial cells seeded on glass coverslips were incu-
bated with FAM-FLICATM Caspase 3&7 assay kit (Immunochemistry
Technologies, Bloomington, MN, USA) for 30 min. as previously
reported [47] and then fixed in 2% paraformaldehyde for 10 min. at
room temperature. Fluorescence was detected by a confocal Leica TCS
SP5 confocal laser scanning microscope with 488-nm excitation wave-
length and 963 oil immersion objective. Caspase-3 activity was also
quantified by flow cytometry: single-cell suspensions were incubated
with FAM-FLICATM for 30 min. at 37°C and then analysed using a FACS-
Canto flow cytometer (Becton-Dickinson).
Determination of intracellular ROS
Guinea pig aortic endothelial cells seeded on glass coverslips were
loaded with the ROS-sensitive fluorescent probe 20,70-dichlorodihydro-
fluorescein diacetate (H2DCFDA; Invitrogen, 2.5 lmol/l) – dissolved in
0.1% DMSO and Pluronic acid F-127 (0.01% w/v) – added to cell cul-
ture media for 15 min. at 37°C [48]. The cells were fixed in 2%
paraformaldehyde for 10 min. at room temperature and the H2DCFDA
fluorescence analysed using a Leica TCS SP5 confocal laser scanning
microscope with 488-nm excitation wavelength and 963 oil immersion
objective. Intracellular ROS levels were also monitored by flow cytome-
try: single-cell suspensions were incubated with H2DCFDA (1 lmol/l)
for 15 min. at 37°C and then analysed using a FACSCanto flow cytome-
ter (Becton-Dickinson).
Evaluation of lipid peroxidation
Lipid peroxidation was investigated by confocal scanning microscopy
using BODIPY 581/591 C11 (Life Technologies, Monza, Italy), a lipophi-
lic fluorescent probe that mimics the properties of natural lipids [49].
BODIPY acts as a fluorescent lipid peroxidation reporter as it shifts its
fluorescence from red to green in the presence of oxidizing agents. Gui-
nea pig aortic endothelial cells cultured on glass coverslips were loaded
with BODIPY, dissolved in 0.1% DMSO (2 lM final concentration in the
culture medium), for 30 min. at 37°C. The cells were fixed in 2%
paraformaldehyde for 10 min. at room temperature and analysed using
a Leica TCS SP5 confocal laser scanning microscope with 581 nm exci-
tation wavelength and 963 oil immersion objective. Lipid peroxidation
was also quantified by flow cytometry: single-cell suspensions were
incubated, in the dark, for 30 min. at 37°C with BODIPY (1 lM) in cell
culture medium and then analysed using a FACSCanto flow cytometer
(Becton-Dickinson).
All the flow cytometry data were analysed using FACSDiva software
(Becton-Dickinson).
Western blotting
After treatments, GPAE cells were lysed in cold buffer (10 mM Tris/HCl
pH 7.4, 10 mM NaCl, 1.5 mM, MgCl2, 2 mM Na2 EDTA, 1% Triton
X-100), added with 109 Sigmafast Protease Inhibitor cocktail tablets.
Total protein content was measured spectrophotometrically using micro-
BCATM Protein Assay Kit (Thermo Fisher-Pierce, Waltham, MA, USA).
Forty microgram of total proteins were electrophoresed by SDS-PAGE
and blotted onto nitrocellulose membranes (Amersham, Cologno Monz-
ese, Italy). The membranes were incubated overnight at 4°C with rabbit
polyclonal anti-eNOS (1:1000; Abcam) and rabbit polyclonal anti-b-actin
antibodies (1:20,000; Sigma-Aldrich), assuming b-actin as control invari-
ant protein. Specific bands were detected using rabbit peroxidase-labelled
Fig. 1 Ex vivo contractility of aortic strips
from guinea pigs of the different experi-
mental groups. (A) Typical tracings in
response to phenylephrine (2 9 107 M)
and acetylcholine (Ach, 2 9 106 M). In
the CS-exposed animals, the amplitude
and slope of both responses are reduced
as compared with the untreated controls.
RLX reverted the tracing amplitude and
slope to a pattern similar to that of the
controls. (B) Mean amplitude of contrac-
tile and relaxant responses to phenyle-
phrine and Ach, respectively, in the
different experimental groups. Amplitudes
of the contractile responses to phenyle-
phrine and the relaxant responses to Ach
are expressed as per cent increase and
decrease, respectively, of the maximal
contraction evoked by 2 9 107 M
phenylephrine, assumed as 100%. Values
are means  S.E.M. (one-way ANOVA test),
n = 6. **P < 0.01, ***P < 0.001 versus
controls; †P < 0.05 and ††P < 0.01 versus
CS-exposed animals.
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secondary antibodies (1:15,000; Vector, Burlingame, CA, USA) and
enhanced chemiluminescent (ECL) substrate (Bio-Rad, Milan, Italy).
Data analysis and statistical tests
The reported data are expressed as the mean  S.E.M. of six animals
per group or at least three independent cell culture experiments. Statis-
tical comparison of differences between groups was carried out using
one-way ANOVA followed by Student–Newman–Keuls multiple comparison
test. A P-value ≤0.05 was considered significant. GraphPad Prism 2.0
statistical program (GraphPad Software, San Diego, CA, USA) was used
for statistical analysis.
Results
Plasma CO levels
The animals of the different experimental groups subjected to chronic
CS had significantly elevated CO levels (CS-exposed: 37.9  3.2;
CS+RLX 1 lg/day: 32.1  3.1; CS+RLX 10 lg/day: 37.5  5.8)
compared with the controls (6.4  0.8: P < 0.001 versus the other
groups). No significant differences were detected among the CS-
exposed groups, suggesting that all the animals were subjected to the
same level of CS-induced toxicity.
Plasma RLX levels
The circulating levels of RLX evaluated at the end of the experiment
were 308  44 pg/ml and 2.5  0.6 ng/ml upon 1 and 10 lg daily
doses respectively. The values measured in the untreated controls
and the CS-exposed animals were consistently below the detection
threshold.
Ex vivo aortic contractility
In aortic strips from the untreated control animals, addition of
phenylephrine to the bath medium caused a rapidly arising contrac-
Fig. 2 Histology of aortas from guinea pigs of the different experimental
groups. (A) Representative pictures of aortic transverse sections: the
control shows continuous endothelial lining and a tunica media made
up of alternate layers of elastic lamellae and smooth muscle cells; CS
shows extended loss of endothelial cells, marked thickening of the
tunica media with disarrangement of smooth muscle cells and accumu-
lation of amorphous material (arrows); RLX treatment at both doses
shows features similar to the control. Insets: details of the aortic intima
showing the presence or absence of the endothelial lining. (B) Morpho-
metric analysis of aortic wall thickness (intima+media): values are
means  S.E.M. (one-way ANOVA test), n = 6. ***P < 0.001 versus con-
trols; †††P < 0.001 versus CS-exposed animals. Haematoxylin & eosin,
magnification 9200, bars = 100 lm.
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tion that reached a plateau phase (mean amplitude 0.20  0.05 g)
(Fig. 1). In phenylephrine-precontracted preparations, Ach caused a
fast relaxation (Fig. 1) that persisted until washout. In aortic strips
from the CS-exposed guinea pigs, both the contractile and the relax-
ant responses to phenylephrine and Ach were significantly reduced in
amplitude and delayed (Fig. 1). In strips from the CS-exposed ani-
mals treated with RLX at both doses, the amplitude of responses to
both phenylephrine and Ach was significantly enhanced as compared
with the CS-exposed animals (Fig. 1). No significant differences were
observed between 1 and 10 lg/day RLX.
Morphology
Histological examination of transverse sections of aorta (Fig. 2A)
showed that the control guinea pigs had thin wall, showing an
intact structure with continuous endothelial lining and alternate
layers of elastic lamellae and smooth muscle cells in the tunica
media. Cigarette smoke exposure caused extended loss of
endothelial cells, significant wall thickening, disarrangement of
smooth muscle cells in the tunica media, some of which showed
cytoplasmic vacuolation, and accumulation of amorphous mate-
rial. Conversely, treatment with RLX at both doses during CS
exposure resulted in an almost complete disappearance of the
noted aortic wall abnormalities. The RLX-induced reduction of
aortic wall thickening caused by CS exposure was confirmed by
the morphometric analysis (Fig. 2B). Ultrastructural examination
(Fig. 3) revealed that, compared with the controls, CS exposure
caused diffuse endothelial cell vacuolation and signs of cell
demise, such as plasma membrane rupture and detachment from
the other cells and the basement membrane; RLX at both doses
prevented these degenerative changes.
Fig. 3 Representative electron micrographs of aortic intima from guinea
pigs of the different experimental groups. The control shows normal
features of endothelial cells (EC), which are bound by tight junctions
(arrowhead); CS exposure causes diffuse endothelial cell vacuolation
and plasma membrane rupture (arrow); RLX at both doses results in a
normal appearance of the endothelial cells. G: well-developed Golgi
apparatus; asterisks, tracts of basement membrane; IEL, inner elastic
lamina; magnification 96000, bars = 1 lm.
Fig. 4 (A) RT-PCR showing the expression of the RLX receptor RXFP1
by GPAE cells. (B) Trypan blue viability test performed on GPAE cells:
compared with the controls, exposure to CSE causes a significant
decrease in cell viability, while pre-treatment with RLX significantly
reduced this effect. RLX per se has no effect on cell viability. Values are
means  S.E.M. (one-way ANOVA test), n = 6. ***P < 0.001 versus con-
trols; ††P < 0.01 versus CSE.
Fig. 5 Evaluation of apoptosis in GPAE cells. (A) Confocal microscopy of GPAE cells subjected to TMRM and caspase-3 activity assays. Exposure to
CSE causes a marked reduction of mitochondrial membrane polarization and increase in caspase-3 activity, which are counteracted by RLX. (B).
FACS analysis confirms the above findings. Values are means  S.E.M. (one-way ANOVA test), n = 3. **P < 0.01, ***P < 0.001 versus control.
††P < 0.01, †††P < 0.001 versus CSE. RLX per se has no pro-apoptotic effect, bar: 20 lm.
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Endothelial cell viability
To investigate the mechanisms of the protection afforded by RLX on
the aortic endothelium upon exposure to CS, we performed a series
of in vitro experiments on primary GPAE cells. These cells were first
shown to express the RLX receptor RXFP1 (Fig. 4A). When exposed
to CSE for 4 hrs, GPAE cells showed a marked viability decrease, as
assayed with the trypan blue exclusion test. Pre-treatment for 24 hrs
with 100 ng/ml RLX significant reduced this adverse effect of CSE
(Fig. 4B). Reduced cell viability by CSE was correlated with the induc-
tion of apoptosis. Exposure to CSE induced a prominent decrease in
mitochondrial membrane polarization, an early apoptotic event, and
increase in caspase-3 activity, a marker of ongoing apoptosis, in
comparison with the untreated controls (Fig. 5A and B). Incubation
with RLX significantly reduced CSE-induced apoptosis (Fig. 5A and
B). Addition of RLX to untreated control cultures had no effect on cell
viability and apoptosis.
Endothelial oxidative injury
Because oxidative injury is a typical detrimental effect of CS (5-10), we
then investigated whether the observed endothelial damage was
related to oxidative stress. In fact, the serum levels of 8-OHdG, a mar-
ker of DNA oxidation, were significantly increased in the guinea pigs
exposed to CS in comparison with the untreated controls, while admin-
istration of RLX at both doses significantly reduced serum 8-OHdG
(Fig. 6A). In keeping with these results, 4-hr exposure of GPAE cells to
CSE caused a robust increase in intracellular ROS (Fig. 6B), resulting
in significantly higher membrane lipid peroxidation (Fig. 6C), as com-
pared with the untreated controls. The treatment with RLX significantly
reduced both these CSE-induced oxidative stress markers (Fig. 6B and
C). Addition of RLX to untreated control cultures had no effect.
Endothelial NOS expression
Cigarette smoke-induced endothelial injury and dysfunction has been
associated with impaired eNOS expression [14–16]. Accordingly, the
current in vivo experiment has shown that CS causes a well-appreci-
able decrease in eNOS immunoreactivity in the residual endothelial
cells of the aortic wall as compared with the untreated controls. This
eNOS impairment was reduced in the animals treated with RLX at
both doses (Fig. 7A). The supportive effect of RLX on eNOS expres-
sion was confirmed in vitro: in fact, eNOS mRNA (Fig. 7B) and protein
expression (Fig. 7C) in GPAE cells were markedly reduced in the
CSE-treated cultures, while incubation with RLX significantly reduced
the CSE-induced eNOS reduction. Addition of RLX to untreated con-
trol cultures had no appreciable effect.
Discussion
The results of the present study show that RLX protects against aortic
dysfunction and endothelial impairment induced by CS. In fact, long-
term administration of RLX to guinea pigs exposed chronically to CS
preserved the responsiveness of isolated aortic strips to phenyle-
phrine and Ach, which was compromised by CS. Namely, the
decreased amplitude of the vasodilatory responses to Ach accounts
for impaired endothelial function, as also reported in previous experi-
mental studies on animals exposed to chronic smoking [12]. On the
other hand, the impairment in contractile response to phenylephrine
observed in the preparations from CS-exposed animals is likely
related to adverse arterial wall remodelling, a typical effect of CS-
induced vascular injury [4, 20]. The improvement of the contractile
response to phenylephrine induced by RLX treatment fits well with
the present observation of preserved histology of the aortic wall and
is consistent with the report that RLX therapy prevents and even
reverses large artery remodelling and fibrosis in a rat model of
chronic hypertension [50]. In our experimental model, CS exposure
and RLX treatment were concurrent, thus the reported findings sup-
port the notion that RLX prevents CS-induced arterial injury and dys-
function but do not provide information to understand whether RLX
treatment could revert established vascular damage because of CS.
The observed preservation of the vasodilatory property of aortas
in the CS-exposed guinea pigs which received RLX can be chiefly
related to the maintenance of the endothelial lining and of adequate
levels of eNOS in endothelial cells, as can be argued from the present
in vivo and in vitro findings. This property of RLX fits well with previ-
ous reports that this hormone can up-regulate NOS expression in
vascular endothelial cells [26–30]. However, RLX may also promote
arterial dilatation by a direct effect on vascular smooth muscle cells,
as reported [29].
Our study indicates that the dysfunctional vasodilatory response
of the aortas in CS-exposed guinea pigs is related to endothelial
impairment because of oxidative stress, as suggested by the rise in
serum 8-OHdG. Indeed, in these animals, the aortic endothelium was
lacking in large tracts of the intima and, when present, showed ultra-
structural signs of cell injury and a remarkable reduction of eNOS
expression. Consistently, exposure of GPAE cells to CSE caused a sig-
nificant reduction of cell viability and induction of apoptosis, which
were closely related to increase in intracellular ROS and lipid peroxi-
dation. The present findings first show that RLX, at physiological cir-
culating levels or nanomolar concentrations in the culture medium,
Fig. 6 Evaluation of oxidative stress. (A) Levels of 8-OHdG, a DNA oxidation marker, in the different groups of animals: compared with the controls,
CS causes a significant increase in 8-OHdG, which was reduced by RLX at both doses. Values are means  S.E.M. (one-way ANOVA test), n = 6.
**P < 0.01, versus control. †P < 0.05 versus CS. (B) Confocal microscopic evaluation of intracellular ROS generation and lipoperoxidation by
H2DCFDA and BODIPY on GPAE cells: both these parameters are enhanced upon CSE treatment and significantly reduced by RLX. (C) FACS analysis
confirms the confocal microscopic findings. Values are means  S.E.M. (one-way ANOVA test), n = 3. ***P < 0.001 versus control. †††P < 0.001
versus CSE. RLX per se has no pro-apoptotic effect, bar: 20 lm.
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protects endothelial integrity and function by reducing oxidative
stress both in vivo and in vitro.
The cellular mechanisms accounting for this antioxidant effect
remain to be elucidated. Preliminary findings from our laboratory
obtained with the oxygen radical absorbance capacity assay indicate
that RLX has no intrinsic antioxidant properties. On the other hand,
RLX administration to GPAE cells markedly increased their endoge-
nous antioxidant capacity: in the presence of CSE, RLX restores it to
levels near to the untreated controls (Supporting Information). It can
be speculated that RLX may up-regulate one or more cellular defence
mechanisms against oxidative stress through activation of PI3 and
MAP kinases, typical downstream pathways of RXFP1 activation in
blood vessels [30, 51]. These signalling pathways are in fact involved
in the cell response to ROS, being able to induce the phosphorylation
of the transcription factor nuclear factor-E2-related factor 2 (Nrf2),
which binds the antioxidant response element within the promoters
of genes encoding antioxidant and detoxifying enzymes [52]. This
hypothesis for the mechanism of action of RLX on cell resistance to
oxidative stress deserves further investigation.
A limitation of this study is that we did not explore in vivo physiologi-
cal parameters, such as blood pressure or pulse pressure, useful to fur-
ther assess RLX’s therapeutic effects. However, the current observation
that RLX is capable of reducing CS-mediated vascular damage and dys-
function may be relevant to human health. In fact, it is known that post-
menopausal women who are smokers have double the risk of CVD, a
discrepancy which has been related to defective ovarian hormones [53].
However, the protection afforded by hormone replacement therapy
(HRT) with oestrogen/progestin is controversial, as some clinical trials
failed to confirm that HRT can be beneficial. Two randomized prospective
primary or secondary prevention trials showed that HRT may actually
increase the risk and events of CVD in post-menopausal women [54].
The failure of HRT in lowering the cardiovascular risk of smoking in
post-menopausal women can be explained considering that cessation of
ovarian function at menopause implies not only a drop in the secretion
of oestrogen and progesterone but also of H2 relaxin, which is mainly
secreted by the corpus luteum [55] and has been credited of major pro-
tective activities on the cardiovascular system [23, 29, 56]. On this
ground, RLX could be viewed as a new therapeutic tool to prevent or
reduce the cardiovascular risk in smokers: this hypothesis is strength-
ened by the successful use of RLX in the treatment of patients with heart
failure demonstrated in a recent clinical trial, which also revealed that the
use of RLX in humans is safe and free of adverse side effects [24, 57].
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Data S1 Oxygen radical absorbance capacity (ORAC) assay.
Fig. 7 Expression of constitutive endothelial NOS (eNOS). (A) eNOS
immunoreactivity in aortic sections from guinea pigs of the different
experimental groups: compared with the control, CS causes a
marked reduction of eNOS immunoreactivity in the endothelial lining,
while this adverse effect is counteracted by RLX at both doses,
magnification 9400, bars = 20 lm. Expression of eNOS mRNA (B)
and protein (C) in GPAE cells evaluated by RT-PCR and Western
blotting, respectively. Compared with the controls, eNOS is reduced
by CSE and maintained by RLX. RLX per se has no appreciable
effects.
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